March 15, 2024
Chugai Pharmaceutical said on March 14 that it has filed its PD-L1 inhibitor Tecentriq (atezolizumab) for an additional indication of alveolar soft part sarcoma, an ultra-rare disease that mainly affects adolescents and young adults. The submission rides on the back...read more